Printer Friendly

DRUG SCREENING SYSTEMS' MARIJUANA TEST CLEARED FOR MARKETING BY THE FDA

DRUG SCREENING SYSTEMS' MARIJUANA TEST CLEARED FOR MARKETING BY THE FDA
 BLACKWOOD, N.J., Jan. 27 /PRNewswire/ -- Drug Screening Systems Inc. (NASDAQ: DRUG) announced today its proprietary on-site drug screening test for THC (marijuana) has been "cleared for marketing" by the U.S. Food and Drug Administration (FDA) and will be marketed, together with the company's other tests for drugs of abuse, in the United States, Europe, South America and the Far East by Wells Fargo Investigative Services and other distributors.
 "We anticipate enthusiastic acceptance of our product line for pre- and post-employment screening by organizations concerned about lost productivity and other adverse effects of drug abuse," Robert G. Wallace, president of Drug Screening Systems, said. "With FDA market clearance behind us, we can now, for the first time, quickly enter the growing market for on-site drug testing in a significant way. This marks a dramatic turning point for Drug Screening Systems as we complete our transformation from a product development company into a major marketer."
 The 510(K) application the company submitted to the FDA included an independent clinical evaluation conducted by the Toxicology Laboratory of the Hospital of the University of Pennsylvania. Results of the clinical evaluation indicated that, as with the company's tests for opiates, methamphetamine and cocaine previously cleared for marketing by the FDA, the reliability and sensitivity of the company's test to detect marijuana in human urine equaled or exceeded that of conventional laboratory screening tests.
 Wells Fargo Investigative Services (a subsidiary of BPS Guard Services) and other distributors will now market the company's full line of tests for use by business, law enforcement and government agencies, and health care professionals. With the expanding international drug trade and the increasing awareness on the part of foreign governments and businesses of the harmful effects of drug abuse, the company anticipates that the international market will play an increasing role in the expansion of its sales.
 Drug Screening Systems is a biochemical diagnostic company engaged in the development, manufacture and marketing of on-site screening tests for drugs of abuse. The company's products are currently sold in the United States for pre-employment screening under the trademark MACH IV SCREEN(R) primarily by Wells Fargo Guard Services, which, along with its affiliates, is the largest private security force in the nation. The company's drug screening tests are also sold throughout Europe, South America and the Far East through distributors and sales agents.
 -0- 1/27/92
 /CONTACT: Gary Nacht of Drug Screening Systems, 609-228-8500/
 (DRUG) CO: Drug Screening Systems Inc. ST: New Jersey IN: MTC SU:


CK-TS -- NY060 -- 3736 01/27/92 12:13 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 27, 1992
Words:436
Previous Article:SUNCOAST PIPELINE NAMES E.J. BURGIN PRESIDENT
Next Article:OSHA CITES IMPERIAL FOODS, CUMMING, GA., FOR SAFETY AND HEALTH VIOLATIONS; PROPOSES $144,500 IN PENALTIES
Topics:


Related Articles
DRUG SCREENING SYSTEMS REPORTS SECOND QUARTER/SIX MONTHS RESULTS
DRUG SCREENING SYSTEMS SUBMITS APPLICATION TO FDA FOR PCP TEST
DRUG SCREENING SYSTEMS' PCP TEST CLEARED FOR MARKETING BY THE FDA
DRUG SCREENING SYSTEMS REPORTS FIRST QUARTER RESULTS; BARBITURATE TEST CLEARED FOR MARKETING BY FDA; CLASS ACTION INSTITUTED
DRUG SCREENING SYSTEMS SIGNS OTC MARKETING AGREEMENT WITH ACCU-SCREEN LABS
EDITEK, INC. LAUNCHES EZ-SCREEN: PCP DRUGS OF ABUSE TEST
EDITEK RECEIVES SECOND VERDICT FDA PRE-MARKET CLEARANCE
FDA PANEL RECOMMENDS CLEARANCE OF STC TEST KITS AND PHARMCHEK(R) SWEAT PATCH
EDITEK LAUNCHES EZ-SCREEN(R) PROFILE(TM) DRUGS OF ABUSE PRODUCT
American Bio Medica Receives FDA Clearance of its 510 (K) Submission

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters